<DOC>
	<DOCNO>NCT01431690</DOCNO>
	<brief_summary>The primary objective study determine effect Epanova® pharmacokinetic anticoagulant activity warfarin . The secondary objective study compare systemic exposure EPA DHA follow multiple-dose administration Epanova® , free fatty acid mixture , Lovaza® , mixture fatty acid ethyl ester , low-fat meal condition since product likely administer patient cardiovascular disease recommend consume low-fat meal .</brief_summary>
	<brief_title>Interaction Epanova Warfarin Pharmacokinetic Anticoagulant Activity Comparison Effects Epanova Lovaza Eicosapentaenoic Acid ( EPA ) Docosahexaenoic Acid ( DHA ) After Low-fat Meals</brief_title>
	<detailed_description />
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Subject candidate must fulfill follow inclusion criterion eligible participation study : 1 . Healthy adult male and/or female , 18 55 year age ( inclusive ) . 2 . Body mass index ( BMI ) ≥ 18 ≤ 29.9 ( kg/m2 ) . 3 . Medically healthy clinically insignificant screen result . Hemoglobin must ≥ low limit normal . 4 . Nontobacco/nicotinecontaining product user minimum 6 month prior dose . 5 . Voluntarily consent participate study follow restriction procedure outline study . 6 . For Warfarin Epanova Arm , females must nonchildbearing potential define undergone sterilization procedure least 6 month prior checkin postmenopausal least 24 consecutive month prior checkin study screen follicle stimulate hormone level &gt; 40 mIU/mL . 7 . For Lovaza Arm , female may nonchildbearing potential ( outline Warfarin Lovaza ) childbearing potential must either sexually inactive ( abstinent ) 14 day prior screen remain 30 day follow final dosing study drug completion subject 's first menstrual cycle follow final dosing study drug , whichever period time longer use one acceptable method birth control . Subjects may exclude study evidence follow criterion screen , checkin , time study appropriate . For arm ( Warfarin Epanova , Lovaza ) 1 . Has history presence significant cardiovascular , pulmonary , hepatic , renal , hematological , gastrointestinal ( GI ) , endocrine , immunologic , dermatologic , neurological , psychiatric disease . 2 . Has positive urine drug/alcohol test screen checkin . 3 . Has positive test human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) . 4 . Has consume fish within 7 day prior checkin . 5 . Has use fish oil , EPA and/or DHA contain supplement within 2 month checkin . 6 . Has history presence alcoholism drug abuse within 2 year prior checkin . 7 . Has know sensitivity allergy soybean , fish , and/or shellfish . 8 . Has hypersensitivity idiosyncratic reaction compound related Epanova® Lovaza® . 9 . Has use prescription medication ( exception hormonal contraceptive female Lovaza arm ) within 14 day prior checkin . 10 . Has use overthecounter ( OTC ) medication , include herbal product ( e.g. , bromelains , danshen , dong quai [ Angelica sinesis ] , garlic , ginko biloba , ginseng , St. John 's wort ) , within 7 day prior checkin . Up 2 g per day acetaminophen allow discretion PI Lovaza arm . 11 . Has use drug know significantly inhibit [ strong moderate ] induce liver enzymes involved drug metabolism [ CYP P450 ] ) within 30 day prior checkin . 12 . Has donate blood significant blood loss within 56 day prior checkin . 13 . Has donate plasma within 7 day prior checkin . 14 . Has participate another clinical trial within 30 day prior checkin . 15 . Is female pregnant lactating . For Warfarin Epanova Arm : 1 . Has take large daily dos Vitamin K ( exceed 25 μg/day ) eat large quantity ( e.g. , average &gt; 4 portion daily ) dark green/leafy vegetable ( e.g. , spinach , kale , collard green , broccoli , Brussels sprout ) 2 month prior checkin . 2 . Is employ involved circumstance would place increase risk hemorrhage ( e.g. , contact sport , strenuous unaccustomed weight lifting , run , bicycle ) . 3 . Has personal familial history bleed disorder ( ) , thromboembolic disease , clinical GI bleeding , history GI surgery except uncomplicated appendectomy cholecystectomy , colorectal surgery polyp , nonmalignant tumor , diverticulum . 4 . Has active severe gingivitis . 5 . Has hypersensitivity idiosyncratic reaction compound related warfarin . 6 . Has recent physical injury ( within 2 week prior screen ) . 7 . Has major surgery within 3 month prior screen . 8 . Is allergic Vitamin K. 9 . Has use nonsteroidal antiinflammatory ( NSAID ) drug within 2 week prior checkin . 10 . Has positive fecal occult blood sample checkin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Eicosapentaenoic Acid</keyword>
	<keyword>Docosahexaenoic Acid</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Hypertriglyceridemia</keyword>
	<keyword>Omega-3 free fatty acid</keyword>
	<keyword>Omega-3 ethyl ester acid</keyword>
	<keyword>Epanova</keyword>
	<keyword>Lovaza</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>low-fat meal</keyword>
</DOC>